Amneal Pharmaceuticals vs Elanco Animal Health
Elanco Animal Health is the larger business, with $4.71bn of revenue in fiscal 2025 against $3.02bn for Amneal Pharmaceuticals (1.6 times as much). Amneal Pharmaceuticals grew faster (8.0% against 6.2%). Amneal Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 2.4% against -4.9%.
| Latest fiscal year | Amneal PharmaceuticalsAMRX, 2025 | Elanco Animal HealthELAN, 2025 |
|---|---|---|
| Revenue | $3.02bn | $4.71bn |
| Revenue growth | 8.0% | 6.2% |
| Net income | $72.1m | −$232m |
| Operating margin | 13.1% | — |
| Net margin | 2.4% | -4.9% |
| Return on equity | — | -3.7% |
| Free cash flow | $270m | $284m |
| Cash | $282m | $545m |
| Total debt | $2.69bn | $4.02bn |
| Debt to equity | — | 61.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 8,500 | 9,000 |
| Market value | $6.60bn | $12.23bn |
| Price vs our value range | Above our value range | Above our value range |
| Moat score | 34 (Weak) | 42 (Weak) |
| Insider trades, 12 months | 0 buys, 7 sales | 11 buys, 1 sales |